Rchr
J-GLOBAL ID：202001020288904569   Update date: Sep. 28, 2024

TSUJI Takahiro

ツジ タカヒロ | TSUJI Takahiro
Affiliation and department：
Fred Hutchinson Cancer Center

About Fred Hutchinson Cancer Center


Job title： Postdoctoral Fellow
Other affiliations (2)：
Research field  (4)： Tumor diagnostics and therapeutics ,  Anatomy ,  Cell biology ,  Respiratory medicine
Research theme for competitive and other funds  (8)：
  • 2022 - 2025 オプト・オミクスが明らかにする脳内微小環境と癌細胞の分子基盤
  • 2022 - 2024 脳内免疫応答に着目した転移性脳腫瘍をターゲットとした治療開発
  • 2021 - 2024 Visualization and Identification of Mechanisms Regulating the Elimination of Metastatic Lung Cancer Cells in the Brain
  • 2021 - 2024 In vivo imaging system for the development of preventive treatment of metastatic brain tumors
  • 2021 - 2023 Interdisciplinary method to elucidate the interaction between brain microenvironment and cancer cells
Show all
Papers (60)：
  • Kazutaka Hosoya, Hiroaki Ozasa, Masahiro Tanji, Hiroshi Yoshida, Hitomi Ajimizu, Takahiro Tsuji, Hironori Yoshida, Yukinori Terada, Noritaka Sano, Yohei Mineharu, et al. Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients. BMC Cancer. 2024. 24. 1
  • Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, et al. Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer. Molecular Cancer Therapeutics. 2023
  • 細谷 和貴, 小笹 裕晃, 橋本 健太郎, 吉田 寛, 大木元 達也, 味水 瞳, 船造 智子, 吉田 博徳, 野溝 岳, 辻 貴宏, et al. 新規TEAD1阻害薬VT103とDabrafenibの併用はBRAF V600E変異肺癌細胞株のアポトーシスを亢進させる(Novel TEAD1 inhibitor VT103 plus dabrafenib promotes apoptosis in BRAF V600E mutated lung adenocarcinoma cell lines). 日本癌学会総会記事. 2023. 82回. 285-285
  • Tatsuya Ogimoto, Hiroaki Ozasa, Hironori Yoshida, Takashi Nomizo, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Masatoshi Yamazoe, Hitomi Ajimizu, et al. CD47 polymorphism for predicting nivolumab benefit in patients with advanced non-small-cell lung cancer. Oncology Letters. 2023. 26. 2
  • 小笹 裕晃, 細谷 和貴, 辻 貴宏, 味水 瞳, 和氣 弘明, 平井 豊博. 肺癌転移性脳腫瘍の生体内観察モデルを用いた,新規治療薬の検討. 日本呼吸器学会誌. 2023. 12. 増刊. 101-101
ｍore...
MISC (55)：
  • Masatoshi Yamazoe, Hiroaki Ozasa, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Yamamoto, Takahiro Tsuji, Ryo Itotani, Yuichi Sakamori, Takashi Nomizo, et al. TEAD single nucleotide polymorphism affects PFS in EGFR-mutation positive lung cancer patients treated with EGFR TKIs. CANCER SCIENCE. 2022. 113. 1014-1014
  • 大木元達也, 小笹裕晃, 橋本健太郎, 吉田寛, 細谷和貴, 山添正敏, 味水瞳, 船造智子, 辻貴宏, 辻貴宏, et al. YAP1 and other factors are associated with initial resistance mechanisms in EGFR mutation-positive lung cancer. 日本癌学会学術総会抄録集(Web). 2022. 81st
  • 細谷和貴, 小笹裕晃, 橋本健太郎, 吉田寛, 大木元達也, 山添正敏, 味水瞳, 船造智子, 辻貴宏, 辻貴宏, et al. Novel TEAD1 inhibitor VT103 promotes apoptosis in patient-derived BRAF V600E mutated lung adenocarcinoma cell lines. 日本癌学会学術総会抄録集(Web). 2022. 81st
  • Masatoshi Yamazoe, Hiroaki Ozasa, Tetsuya Ohgimoto, Kazutaka Hosoya, Hitomi Ajimizu, Tomoko Funazo, Yuto Yasuda, Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, et al. Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer. CANCER RESEARCH. 2021. 81. 13
  • Masatoshi Yamazoe, Hiroaki Ozasa, Tatsuya Ogimoto, Kazutaka Hosoya, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, et al. Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer. CANCER SCIENCE. 2021. 112. 890-890
ｍore...
Lectures and oral presentations  (8)：
  • 生体内リアルタイムイメージングが可視化する脳内腫瘍微小環境の自然免疫応答
    (バイオメディカル・フォーラム 2023)
  • 生体内イメージング技術が可視化する癌細胞と脳内免疫微小環境の相互作用
    (第128回日本解剖学会総会・全国学術集会 2023)
  • 転移性脳腫瘍モデルを用いた転移制御因子の探索
    (第62回日本肺癌学会学術集会 2021)
  • Microglia phagocytose metastatic tumors and suppress metastasis formation
    (2021)
  • 脳のリアルタイムin vivoイメージングはミクログリアの癌細胞に対する動的反応を可視化する
    (第126回日本解剖学会総会・全国学術集会 / 第98回日本生理学会大会 合同大会 2021)
ｍore...
Education (2)：
  • 2014 - 2018 Kyoto University Department of Respiratory Medicine, Graduate School of Medicine PhD course
  • 2002 - 2008 Faculty of Medicine, Kyoto University
Professional career (2)：
  • PhD (Medical Science) (Kyoto University)
  • MD (Kyoto University)
Work history (8)：
  • 2024/07 - 現在 日本学術振興会 海外特別研究員
  • 2024/07 - 現在 Fred Hutchinson Cancer Center Metastatic Microenvironment Lab Postdoctoral Fellow
  • 2020/09 - 2024/07 Nagoya University Research Fellow
  • 2021/04 - 2024/03 Japan Society for the Promotion of Science Research Fellow
  • 2019/04 - 2020/09 Kyoto University Hospital Department of Respiratory Medicine Clinical Fellow
Show all
Awards (6)：
  • 2022/07 - Wakate Dojo Best Presentation Award
  • 2021/09 - Graduate School of Medicine, Kyoto University KMYIA (Young Investigator Award) YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
  • 2021/04 - American Association for Cancer Research AACR-Bristol Myers Squibb Scholar-in-Training Award Real time in vivo imaging of brain metastasis visualized dynamic reaction of microglia against cancer cells
  • 2020/11 - The Japan Lung Cancer Society Young Investigator Award YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
  • 2020/02 - Health-promoting Association for Respiratory Medicine of West Japan Medical Prize 2019 Research Fields YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Show all
Association Membership(s) (7)：
日本解剖学会 ,  日本生理学会 ,  American Association for Cancer Research ,  THE JAPAN LUNG CANCER SOCIETY ,  THE JAPANESE CANCER ASSOCIATION ,  THE JAPANESE RESPIRATORY SOCIETY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM